中國環保科技(00646.HK)溢價約14.6%發新股 清償應付款項
中國環保科技(00646.HK)公布,與認購人獨立第三方王宇山簽署了認購及清償協議,王宇山將認購420萬股公司新發行股份,每認購股份的發行價格為0.6075元,涉資255萬元。
每股認購股份發行價格較上周五(19日)所報每股收盤價0.53港元溢價約14.62%。王宇山為自2019起向集團提供多種管理及諮詢服務的執業會計師,欠付認購人的金額與未支付的專業服務有關;應在完成時通過與集團應付王宇山的擬清償應付款抵銷的方式支付認購價,且公司應向認購人配發和發行認購股份,作為對集團擬清償應付款的全部和最終清償。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.